Concepedia

Frédéric Stauffer

FS

20

Publications

2K

Citations

15

H-Index

1997

Active since

Affiliations

Novartis (Switzerland)(Current)

Novartis Institutes for BioMedical Research

Novartis (United States)

Novartis (China)

Scripps Research Institute

Frédéric Stauffer is an author at Novartis (Switzerland) specializing in medicine, drug discovery, and pharmacology.

Top concepts

Publications per year

1997–2025

20

Publications

20

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen et al. · Molecular Cancer Therapeutics · 2008 · 1.1K citations · Full text

Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging

Christian Schnell, Frédéric Stauffer, Peter R. Allegrini et al. · Cancer Research · 2008 · 174 citations

, , +17

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

Romina Marone, Dominik Erhart, Ann C. Mertz et al. · Molecular Cancer Research · 2009 · 124 citations

Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway

Frédéric Stauffer, Sauveur-Michel Maira, Pascal Furet et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 84 citations · Full text

, , +6

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors

Klemens Hoegenauer, Nicolas Soldermann, Frédéric Stauffer et al. · ACS Medicinal Chemistry Letters · 2016 · 65 citations · Full text

Rows per page

1–5 of 20